Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2006-006653-27-DE
EUCTR2006-006653-27-DEActive, not recruitingNot Applicable

Phase IIa, single-center, randomized, double-blind, vehicle-controlled study to determine the efficacy and safety/tolerability of a topical riluzole formulation in patients with atopic eczema - Atopic eczema

Biofrontera Bioscience GmbH0 sitesStarted: February 5, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •All of the following criteria have to be met for inclusion of a volunteer in the study:
  • •signed written informed consent obtained;
  • •male or female subjects, 18 to 64 years;
  • •manifest atopic dermatitis diagnosed according to Hanifin and Rajka (3);
  • •two comparable lesional areas of 20 - 50 cm2 with a distance of at least 5 cm, clinical condition of atopic eczema mild to moderate;
  • •TEWL in the lesional areas at least 12 g/m²h, TEWL value differences = 30 % are allowed between both lesional areas;
  • •the physical examination must be without further disease findings unless the investigator considers an abnormality to be clinically irrelevant;
  • •sexually active females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective medically accepted contraceptive regimen: systemic contraceptive (combined oral contraceptive, implant, injection), safe intrauterine device (IUD).
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Subjects are to be excluded from the study when one or more of the following conditions are met:
  • •acne, suntan, eczema other than Atopic eczema, hyper- or hypopigmentation or tattoos in the treatment areas;
  • •dark-skinned persons whose skin color prevents ready assessment of skin reactions;
  • •evidence of drug or alcohol abuse;
  • •pregnancy or nursing;
  • •UV-therapy within 6 weeks before first treatment;
  • •participation in another clinical study involving pharmaceutical products in the 28 days preceding or during the study;
  • •symptoms of a clinically significant illness that may influence the outcome of the study in the month before and during the study;
  • •known allergic reactions to components of the study preparations;
  • •liver disease or transaminase values > 3 times upper normal limit;
  • •kidney insufficieny;
  • •neutropenia;
  • •systemic treatment or locally acting medications which might counter or influence the study aim (e.g. glucocorticosteroids or medication that influences liver function) within four weeks before first study treatment (exception: asthma may be found in subjects with atopic dermatitis, therefore inhalation with corticosteroids in subjects with asthma accompanying atopic dermatitis will be allowed at a dose not exceeding 1 mg/day. The dosage should remain constant throughout the study period);
  • •in the opinion of the investigator or physician performing the initial examination the subject should not participate in the study, e.g. due to probable noncompliance or inability to understand the study and give adequately informed consent;
  • •subject is institutionalized because of legal or regulatory order.

Investigators

Similar Trials

Active, not recruiting
Not Applicable
Comparison of defined skin parameters in two comparable lesional skin areas after topical treatment with Tarenflurbil Spray or Placebo
EUCTR2011-002571-42-DEGALENpharma GmbH
Suspended
Phase 2
Clinical trial, phase II, to evaluate rhEGF efficacy and safety at a dose of 25 or 75 micrograms intralesionally in patients with diabetic foot ulcer (Wagner grade 1 or 2).Patients with diabetic foot ulcer (Wagner grade 1 or 2).Foot UlcerLeg UlcerSkin UlcerDiabetic AngiopathiesVascular DiseasesDiabetes ComplicationsDiabetic NeuropathiesEndocrine System DiseasesCardiovascular DiseasesDiabetic FootDiabetes Mellitus
RPCEC00000048Center for Genetic Engineering and Biotechnology (CIGB), Havana.35
Active, not recruiting
Phase 1
A trial to evaluate the immunogenicity and safety of a vaccine against influenza at two dose levels (300µg and 480 µg) compared to the vaccin at 180µg and placebo in healthy volunteers between 18 and 55 years and in healthy subjects aged 65 years and older.The study is being conducted in healthy volunteers for the prophylaxis of influenza infection.MedDRA version: 21.1Level: PTClassification code 10059429Term: Influenza immunisationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2021-002535-39-BEOsivax238
Active, not recruiting
Not Applicable
Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an a4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate.
EUCTR2004-004022-27-ESF.Hoffmann - La Roche Ltd160
Active, not recruiting
Phase 1
A Phase 2a study to evaluate, safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with amyotrophic lateral sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2020-005971-11-DEAL-S Pharma, AG63